WealthTrust Axiom’s Biocept, Inc. BIOC Stock Holding History

WealthTrust Axiom’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-16	Closed	-$298K	–	230
2017 Q1	$298K	Buy	+16	New	+$272K	0.11%	158

Other funds holding BIOC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WealthTrust Axiom's BIOC Position: Q2 2017 in Review

WealthTrust Axiom sold out of Biocept, Inc. (BIOC) in Q2 2017, closing a stake of 16 shares — an estimated $298K sold.

WealthTrust Axiom first reported a position in BIOC in Q1 2017 and held it in 1 quarter. The position peaked at $298K in Q1 2017. 15 funds tracked by Wall St. Rank hold BIOC as of Q2 2017.

WealthTrust Axiom reported no remaining Biocept, Inc. position as of Q2 2017 after selling out during the quarter.
WealthTrust Axiom sold 16 Biocept, Inc. shares in Q2 2017, an estimated $298K.
WealthTrust Axiom first reported a position in Biocept, Inc. in Q1 2017 and held it in 1 quarter.
WealthTrust Axiom's Biocept, Inc. position peaked at $298K in Q1 2017.
15 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2017.

Based on WealthTrust Axiom's 13F filing for Q2 2017, filed 31 Jul 2017.